MX2020004833A - Un poliepitopo quimerico del virus del zika que comprende proteinas no estructurales y su uso en una composicion inmunogenica. - Google Patents

Un poliepitopo quimerico del virus del zika que comprende proteinas no estructurales y su uso en una composicion inmunogenica.

Info

Publication number
MX2020004833A
MX2020004833A MX2020004833A MX2020004833A MX2020004833A MX 2020004833 A MX2020004833 A MX 2020004833A MX 2020004833 A MX2020004833 A MX 2020004833A MX 2020004833 A MX2020004833 A MX 2020004833A MX 2020004833 A MX2020004833 A MX 2020004833A
Authority
MX
Mexico
Prior art keywords
immunogenic composition
structural proteins
zika virus
polyepitope
zikv
Prior art date
Application number
MX2020004833A
Other languages
English (en)
Inventor
Etienne Simon-Loriere
Claude Roth
Anavaj Sakuntabhai
Felix Delgado
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of MX2020004833A publication Critical patent/MX2020004833A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se dirige a un poliepítopo quimérico del virus de Zika (ZIKV) que comprende proteínas no estructurales y su uso En una composición inmunogénica. La presente invención proporciona medios, en particular polinucleótidos, vectores y células que expresan tal poliepítopo quimérico. La presente invención también se refiere a una composición o una vacuna que comprende al menos uno de tal poliepítopo, polinucleótido, vector o célula hospedera para usar en la prevención de una infección por ZIKV en un sujeto humano, o para usar en la prevención de Infecciones por ZIKV y virus del dengue (DENV) en un sujeto humano.
MX2020004833A 2017-11-09 2018-11-08 Un poliepitopo quimerico del virus del zika que comprende proteinas no estructurales y su uso en una composicion inmunogenica. MX2020004833A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17306553 2017-11-09
PCT/EP2018/080677 WO2019092142A1 (en) 2017-11-09 2018-11-08 A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition

Publications (1)

Publication Number Publication Date
MX2020004833A true MX2020004833A (es) 2021-01-08

Family

ID=60574493

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004833A MX2020004833A (es) 2017-11-09 2018-11-08 Un poliepitopo quimerico del virus del zika que comprende proteinas no estructurales y su uso en una composicion inmunogenica.

Country Status (12)

Country Link
US (2) US11305003B2 (es)
EP (1) EP3707154A1 (es)
JP (1) JP7225254B2 (es)
KR (1) KR20200090186A (es)
CN (1) CN111683959A (es)
AU (1) AU2018365296B2 (es)
BR (1) BR112020009157A2 (es)
CA (1) CA3079776A1 (es)
MX (1) MX2020004833A (es)
PH (1) PH12020550569A1 (es)
SG (1) SG11202004234SA (es)
WO (1) WO2019092142A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806393B2 (en) * 2017-02-10 2023-11-07 La Jolla Institute For Allergy And Immunology Flavivirus peptide sequences, epitopes, and methods and uses thereof
CN111683959A (zh) 2017-11-09 2020-09-18 巴斯德研究院 包含非结构蛋白的寨卡病毒嵌合多表位及其在免疫原性组合物中的用途
BR112020012021A2 (pt) 2018-01-06 2020-12-22 Emergex Vaccines Holding Limited Peptídeos associados a mhc de classe i para prevenção e tratamento de múltiplos flavivírus
CN113528465B (zh) * 2020-04-20 2023-07-11 中国人民解放军军事科学院军事医学研究院 包含突变的寨卡病毒全基因组cDNA的DNA分子及其应用
EP4604993A2 (en) * 2022-10-21 2025-08-27 Institut Pasteur Polynucleotides and lentiviral vectors expressing non-structural antigens of a flavivirus selected from the group of denv, zikv and yfv, inducing protective cd8+ t-cell immunity in a host

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1375512E (pt) 2002-06-20 2009-09-23 Pasteur Institut Adnc infeccioso de uma estirpe de vacina aprovada do vírus do sarampo. utilização de composições imunogénicas
ES2427139T3 (es) 2002-06-20 2013-10-29 Institut Pasteur Virus recombinantes del sarampión que expresan epítopos de antígenos de virus de ARN y uso de los virus recombinantes para la preparación de composiciones de vacuna
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8158413B2 (en) 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine
DK1939214T3 (da) 2006-12-22 2013-10-14 Pasteur Institut Celler og metodik til at generere ikke-segmenterede negativstrengede RNA-vira
JP5773648B2 (ja) 2007-08-03 2015-09-02 インスティチュート・パスツールＩｎｓｔｉｔｕｔ Ｐａｓｔｅｕｒ レンチウイルス遺伝子導入ベクター及びそれらの医薬品への適用
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
EP2755693A4 (en) 2011-09-12 2015-05-20 Moderna Therapeutics Inc MANIPULATED NUCLEIC ACIDS AND METHOD OF APPLICATION THEREFOR
EP2712871A1 (en) 2012-09-27 2014-04-02 Institut Pasteur Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
US20170173128A1 (en) 2013-12-06 2017-06-22 Moderna TX, Inc. Targeted adaptive vaccines
EP2959915A1 (en) * 2014-06-23 2015-12-30 Institut Pasteur A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
EP3031923A1 (en) 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
GB201508099D0 (en) * 2015-05-12 2015-06-24 Isis Innovation Dengue vaccines
US20180185467A1 (en) 2015-06-22 2018-07-05 President And Fellows Of Harvard College Compositions and methods for modulating viral infection
US10474927B2 (en) * 2015-09-03 2019-11-12 Stc. Unm Accelerated precomputation of reduced deformable models
US11434259B2 (en) * 2016-01-25 2022-09-06 Iogenetics, Llc Modified Zika virus NS1 protein with reduced cross-reactive immunogenicity
SG11201806340YA (en) 2016-02-17 2018-09-27 Curevac Ag Zika virus vaccine
WO2017189891A1 (en) * 2016-04-27 2017-11-02 Middle Tennessee State University Methods for treating zika viral infections and associated complications
US10378069B2 (en) * 2016-06-27 2019-08-13 Abbott Molecular Inc. Compositions and methods for detecting zika virus
US10632185B2 (en) * 2016-07-08 2020-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric west nile/zika viruses and methods of use
CA3030154A1 (en) * 2016-07-08 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric dengue/zika viruses live-attenuated zika virus vaccines
US11666649B2 (en) * 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
AU2017405996B2 (en) * 2017-03-27 2025-03-27 The University Of Queensland Chimeric insect-specific flaviviruses
CN111683959A (zh) 2017-11-09 2020-09-18 巴斯德研究院 包含非结构蛋白的寨卡病毒嵌合多表位及其在免疫原性组合物中的用途

Also Published As

Publication number Publication date
CA3079776A1 (en) 2019-05-16
EP3707154A1 (en) 2020-09-16
KR20200090186A (ko) 2020-07-28
US20220233678A1 (en) 2022-07-28
PH12020550569A1 (en) 2021-04-19
SG11202004234SA (en) 2020-06-29
JP7225254B2 (ja) 2023-02-20
US11872276B2 (en) 2024-01-16
WO2019092142A1 (en) 2019-05-16
AU2018365296B2 (en) 2023-11-23
JP2021502115A (ja) 2021-01-28
BR112020009157A2 (pt) 2020-10-27
US11305003B2 (en) 2022-04-19
AU2018365296A1 (en) 2020-05-21
CN111683959A (zh) 2020-09-18
US20200282043A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
MX2020004833A (es) Un poliepitopo quimerico del virus del zika que comprende proteinas no estructurales y su uso en una composicion inmunogenica.
PH12016502554B1 (en) A dengue virus chimeric polyepitope composed of fragments of non structural proteins and its use in an immunogenic composition against dengue virus infection
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
CL2019000993A1 (es) Meganucleasas diseñadas específicamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b.
MX2017012097A (es) Variantes de virus adenoasociado y métodos de uso de estas.
AR101814A1 (es) Partícula de tipo virus flavivirus
MX2022003658A (es) Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb.
MY189334A (en) Lentiviral vector-based japanese encephalitis immunogenic composition
UY35131A (es) Composiciones, métodos y usos de construcciones de virus del dengue de serotipo-4
AR093578A1 (es) Metodos para la elaboracion de polipeptidos procesados proteoliticamente
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
AR100606A1 (es) Variantes de lipasas y polinucleótidos que las codifican
CL2015002741A1 (es) Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos
PE20181087A1 (es) SISTEMA VECTOR DE ADENOVIRUS AVIAR 9 (FAdV-9) Y METODOS ASOCIADOS
AR094810A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna
ZA202003070B (en) Lassa vaccine
PH12017501100B1 (en) Recombinant swinepox virus and vaccines
MX2017008342A (es) Composiciones de vacuna para el virus del dengue y metodos de uso de las mismas.
PH12020551944A1 (en) Reverse peptide vaccine
BR112016029201A2 (pt) vírus do oeste do nilo/dengue quiméricos e métodos de uso
CL2014000551A1 (es) Célula de levadura con un vector de expresión que comprende un polinucleótido con la secuencia de la proteina de cápside de vp2 del virus de la necrosis pancreática infecciosa (ipnv) y con la secuencia de uno o mas epítopos de la hemaglutinina del virus de la anemia infecciosa del salmón; alimento para peces que comprende la célula de levadura; vacuna oral para peces.
BR112015025420A2 (pt) expressão de inibidores do hiv por células-tronco mesenquimais
AR113488A1 (es) VARIANTES DE a-AMILASA Y POLINUCLEÓTIDOS QUE LAS CODIFICAN
EA202191862A3 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
AR109734A1 (es) Composiciones y métodos de tratamiento de la infección persistente por el virus del papiloma humano (hpv)